DX 2206
Alternative Names: DX-2206; DXP-106; IL1RAP monoclonal antibody - Singlomics BiopharmaceuticalsLatest Information Update: 12 Jul 2024
At a glance
- Originator Singlomics Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-1 receptor accessory protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer